Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Jim Cramer, the host of Mad Money, reflected on the uncertainty surrounding the year 2025, focusing on several macroeconomic ...

Thermo Fisher Scientific, Horizon Discovery, OriGene Technologies, QIAGEN, and GeneCopoeia Lead the Competition MicroRNA ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.